Discover Great Companies Discover Great Clients
Popularity  3.9万   |   Followers  15   |   Likes  13   |   Feedback  8 Claim this company

A medical device enterprise dedicated to minimally invasive treatment

No.174 Binjiang District Popularity Ranking Hangzhou Zhejiang No.25 Zhuan Yong Equipment No.37 Healthcare Supplies No.37 Jian Kang Chan Industries No.38 Medical Products No.54 Healthcare Technology No.63 Medical Devices No.65 Equipment Manufacturing No.69 Electromechanical Equipment Dao Pipes Ren Gong Qi Guan Dao Guan Jie Ru Jie Gou Xing Xin Zang Bing 专精特新小巨人企业 科技小巨人企业 企业技术中心 省级高新技术企业 总部企业 高新技术企业 NMPA认证
More

Company Overview

  • Nature: Listed Company Size: 500-999 employees Founded: 17年
  • Industry: Medical Equipment/Devices
  • Full name: Hangzhou Qiming Medical Device Co., Ltd.。

Development Stage

  • Stage: IPO, 。
  • Honors: 2021中国新经济500强 2023中国企业慈善公益500强 专精特新小巨人企业 科技小巨人企业 According to algorithm
  • News: 2022-07-12:启明医疗经导管人工肺动脉瓣膜系统获批上市。
  • Salary: 58.6% of positions earn 6-15K, In 2026 vs last yeardecreased by 7%.。Master's salary: ¥26.7K.
  • R&D: "Other (R&D and Technical)" demand: 9.4%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 7.5%, "Mechanical/Instrumentation": 4.7%。
  • Recruiting: In 2026 vs 2025grew by 5%. Demand for highly educated talent: Master's: 8.
  • Requirement: Education: 本科 leads with 66%. Experience: 不限 leads with 40.6%.
  • Region: Distributed across 4 regions, 杭州: 66%, 北京: 8.5%, 广州: 5.7%, 上海: 4.7%.

About the Company

[Summary] A medical device enterprise dedicated to minimally invasive treatment

Hangzhou Qiming Medical Device Co., Ltd. was founded in 2009 and is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), dedicated to the research, development and industrialization of transcatheter treatment products for structural heart disease. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 10, 2019, with stock code 02500. Venus Medtech's full series of "Intelligent Manufacturing in China" valve products have entered more than 60 countries and regions worldwide, with footprints in Asia, Europe, South America and North America.

【Comprehensive Pipeline Leadership】
Currently, Venus Medtech has established a comprehensive overall solution for structural heart disease, covering heart valve diseases such as aortic valve, pulmonary valve, mitral valve and tricuspid valve, and also including hypertrophic cardiomyopathy, renal sympathetic denervation for hypertension, and surgical ancillary products, forming a complete pipeline.
The company has significant first-mover advantages in innovative product development. Its key products VenusA-Valve and VenusA-Plus are the world's first and second-generation TAVR products approved by NMPA and launched in China. VenusA-Valve is also the only product in China with up to 11 years of follow-up data. The company's international flagship product, the transcatheter pulmonary valve replacement (TPVR) system VenusP-Valve, has obtained EU CE MDR certification and has been approved for marketing by China's National Medical Products Administration (NMPA). It is the only self-expanding TPVR product approved for marketing in China and Europe; in 2023, it obtained Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA), becoming the only Chinese-made artificial heart valve approved by the FDA for clinical research.
The company's diversified product pipeline continues to achieve innovative breakthroughs, and multiple products have entered a new stage in mainstream global markets. The international multicenter clinical research protocol for the new-generation balloon-expandable dry valve Venus-Vitae SMART-ALIGN was grandly announced in 2023 at PCR London Valves, the top global event in the field of heart valve intervention. The new-generation fully deployable and fully recapturable dry valve product Venus-PowerX was approved for marketing in Argentina, successfully assisting multiple Latin American patients and bringing high-quality Chinese heart valve disease solutions to countries along the Belt and Road. The international multicenter clinical progress of the innovative transcatheter valve replacement system Cardiovalve is advancing rapidly, and its pivotal clinical study TARGET CE for tricuspid regurgitation covers dozens of renowned cardiovascular centers in Europe and North America.

【Strong R&D and Production Capabilities】
The company has a strong R&D and operations team, with a technical team composed of medical experts, valve and cardiac catheter research experts, and materials experts, achieving strong multidisciplinary integration. As of the end of April 2025, Venus Medtech had a total of 894 patents and patent applications, including 485 granted invention patents, with major countries and regions covered including China, the United States, Europe, Japan, Canada, Russia, India, Brazil, and others.
As a local innovative enterprise, Venus Medtech has won numerous awards and honors, including awards under the 12th Five-Year and 13th Five-Year National Science and Technology Support Programs assessed by the Ministry of Science and Technology of China, the second batch of national specialized and sophisticated "Little Giant" enterprises, the China Excellent Patent Award, Excellent Domestic Medical Equipment Products, and the National High-tech Enterprise title.

【Innovation-Led Development for the Future】
In the future, Venus Medtech will focus on new materials, bionics, image fusion technology and digital sensing, continuously updating and iterating and driving innovation to meet the vast needs of doctors and patients. As a leader in the heart valve field, the company hopes that the Venus Medtech model can provide a strong reference for the development of China's innovative medical industry. Innovation leads the future, and Venus Medtech will continue to be committed to the R&D and commercialization of innovative medical devices for structural heart disease, accelerating Chinese innovation and benefiting the world.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Venus Medtech Financing History (7 rounds)

Manage
IPO
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal:

Venus Medtech How Fast Is Hiring Growing? (47 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 82%
  • 2024: Down 49%
  • 2023: Down 68%
  • 2022: Down 20%
Venus Medtech Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Venus Medtech Campus Recruitment & Advanced Degree Talent Demand
Interns 1 Master's 8
Note: How fast is hiring at Hangzhou Qiming Medical Device Co., Ltd. growing? Venus Medtech2026: 86 openings (up 5%), 2025: 82 openings (up 82%), 2024: 45 openings (down 49%), 2023: 89 openings (down 68%), 2022: 277 openings (down 20%), 2021: 345 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Venus Medtech Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Flat 0%-
  • 2024: Down 71%
  • 2023: Down 79%
  • 2022: Up 267%
Venus Medtech Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Hangzhou Qiming Medical Device Co., Ltd. growing? Venus MedtechMaster's recruitment over the years: 2025: 2 openings (flat), 2024: 2 openings (down 71%), 2023: 7 openings (down 79%), 2022: 33 openings (up 267%), 2021: 9 openings. Venus Medtech master talent ranking in Hangzhou: #223, Venus Medtech master salary mostly around 20-50K.

Venus Medtech Doctoral Degree Job Demand Analysis

(More)
N/A
Growth Rate
Venus Medtech Doctoral Hiring by Year: 2022 — 1 more jobs than 2021
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Hangzhou Qiming Medical Device Co., Ltd. growing? Venus MedtechDoctorate recruitment over the years: 2022: 3 openings (up 267%), 2021: 2 openings.

Venus Medtech R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Hangzhou Qiming Medical Device Co., Ltd.? Based on an analysis of Venus Medtech's job postings over the past year, "Other (R&D and Technical)" demand: 9.4%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 7.5%, "Mechanical/Instrumentation": 4.7%, "Medical & Health/Beauty & Healthcare": 2.8%, "Computer/Network/Technology": 2.8%. For reference only.

Venus Medtech — What Are the Salaries Like? (106 records)

Manage
salary range: 2K - 50K, 58.6% of roles pay ¥6-15K
Note: salary statistics are based on 106 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Hangzhou Qiming Medical Device Co., Ltd.?Venus Medtech58.6% of positions earn 6-15K, Fresh graduate salary: ¥5.5K。Hangzhou salary ranking top 45,销售类 average salary ¥12.0K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Venus Medtech

(More)
Are salaries high at Hangzhou Qiming Medical Device Co., Ltd.? We provide: Sales, Management Trainee, Process Engineer, Finance Specialist, R&D Engineer, Key Account, Accountant, Medical Devices, Customer Specialist, Account Manager, Marketing, Materials Engineer, QA, HR Specialist, Analyst, Business Specialist, Intern, Process Manager, Materials Specialist, Regulatory Affairs Specialist. Click to view detailed salary analysis by job.

Venus Medtech — Fortune 500? (More)

Yes, ranked in 中国新经济500强:

  • NO.369 2021中国新经济500强 >

Yes, ranked in 中国企业慈善公益500强:

  • NO.119 2023中国企业慈善公益500强 >

Venus Medtech honors, qualifications & industry associations

Job Category

  • 销售类
    33% of total 33%
  • 工厂生产类
    19.8% of total 19.8%
  • 培训生类
    17.9% of total 17.9%
  • 技工类
    17% of total 17%

Education

  • 本科
    66% of total 66%
  • 大专
    18.9% of total 18.9%
  • 硕士
    12.3% of total 12.3%
  • 不限
    1.9% of total 1.9%

Experience

  • 不限
    40.6% of total 40.6%
  • 3-5年
    25.5% of total 25.5%
  • 1-3年
    22.6% of total 22.6%
  • 5-10年
    8.5% of total 8.5%
View Detailed Analysis

What does Hangzhou Qiming Medical Device Co., Ltd. require? Who is Venus Medtech hiring? Venus Medtech recruitment: 销售类占比最多占33%,其次是工厂生产类占19.8%. What education can get in at Venus Medtech? 本科占比最多占66%,其次是大专占18.9%. High education required at Venus Medtech? 硕士占12.3%. Work experience required at Venus Medtech? 不限占比最多占40.6%,其次是3-5年占25.5%. Where are the job locations at Venus Medtech? 杭州占比最多占66%,其次是北京占8.5%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 44,101.1443万(元)
Legal Representative: LIM HOU-SEN
Date Established:
Credit Code: 91330100691707450N
Registered Address: 浙江省杭州市滨江区江陵路88号2幢3楼311室

Partners & Suppliers

为启明医疗提供经导管心脏瓣膜临床试验服务 Source
供应商 医疗器械企业
联合开展介入医疗器械研发与临床转化 Source
合作客户 医疗器械
提供心脏瓣膜等医疗器械零部件 Source
合作客户 医疗器械供应链
开展经导管心脏瓣膜技术的产学研合作 Source
供应商 高校/研究院合作
2021年签署战略合作协议,共同推广经导管主动脉瓣置换术(TAVR)产品 Source
合作客户 战略合作

People who follow Venus Medtech also follow

Venus Medtech Competitors (Similar Companies)

饮料 瓶装水 蒸馏水 饮用水
美蛙鱼头 基础教育 区域经济 教育
物流/运输 城市配送 仓储 多式联运
消防设施工程 机电安装 送变电 消防
“Automotive parts, molds and fixtures”
环境监测 环境监测系统 环保/节能 监测设备
物联网/IoT IT基础设施 服务外包 人力资源/HR外包
“Home furnishing brand operator”
服装/服饰 纺织 皮革 家纺
储能电池 动力电池 储能 蓄电池
“Benefit farmers, nourish consumers”
印刷/包装 环保包装 礼品盒 电子产品包装
母婴健康 早教/早期教育 抗衰老 健康管理
“Products for the diagnosis and treatment of allergic diseases”
“Provider of solutions for global public safety and intelligent transpo”

Discover Great Companies, Discover Great Clients

杭州公司名录 杭州“Binjiang District”公司名录 杭州“医疗器械”公司名录 杭州“医疗科技”公司名录 杭州“机电设备”公司名录 杭州“健康产业”公司名录 杭州“专用设备”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates